Cite
HARVARD Citation
Welling, D. et al. (2021). Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas. Laryngoscope investigative otolaryngology. 6 (5), pp. 1008-1019. [Online].